TC
CKPT

TwinBeech Capital’s Checkpoint Therapeutics CKPT Stock Holding History

TwinBeech Capital’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-113,152
Closed -$14.3M – 652
2022
Q4 		$14.3M Buy
+113,152
New +$815K 0.27% 106

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

TwinBeech Capital's CKPT Position: Q1 2023 in Review

TwinBeech Capital sold out of Checkpoint Therapeutics (CKPT) in Q1 2023, closing a stake of 113,152 shares — an estimated $14.3M sold.

TwinBeech Capital first reported a position in CKPT in Q4 2022 and held it in 1 quarter. The position peaked at $14.3M in Q4 2022. 34 funds tracked by Wall St. Rank hold CKPT as of Q1 2023.

  • TwinBeech Capital reported no remaining Checkpoint Therapeutics position as of Q1 2023 after selling out during the quarter.
  • TwinBeech Capital sold 113,152 Checkpoint Therapeutics shares in Q1 2023, an estimated $14.3M.
  • TwinBeech Capital first reported a position in Checkpoint Therapeutics in Q4 2022 and held it in 1 quarter.
  • TwinBeech Capital's Checkpoint Therapeutics position peaked at $14.3M in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2023.

Based on TwinBeech Capital's 13F filing for Q1 2023, filed 15 May 2023.